The Board in its meeting held on 12 August 2026 approved Financial Results for the quarter ended June 30, 2026

Date: August 12, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relation Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block-G, Dalal Street, Bandra-Kurla Complex, Mumbai - 400001. Bandra (East), Mumbai - 400051. Scrip Code: 524404 Symbol: MARKSANS Sub: Outcome of Board Meeting Dear Sir/Madam, Pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) and other regulations, if applicable, we enclose herewith the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30, 2026 approved by the Board of Directors of the Company at its Meeting held today i.e. August 12, 2026 along with Limited Review Reports thereon. Pursuant to Regulation 33 of the Listing Regulations as amended, we hereby declare that M/s. MSKA & Associates LLP, Chartered Accountants, the Statutory Auditors of the Company have submitted the Limited Review Reports for Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30, 2026 with an unmodified opinion. The aforesaid information is also available on the website of the Company at http://www.marksanspharma.com/quarterly-results.html The meeting commenced at 10:50 a.m. and concluded at 12:10 p.m. We request you to note the aforesaid in your records. Thanking You, Yours faithfully, For Marksans Pharma Limited Harshavardhan Panigrahi Company Secretary Encl. As Above Marksans Pharma Ltd. 11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000 E-mail: companysecretary@marksanspharma.com www.marksanspharma.com MS K A & ASSOCiateS LLP :(?2. Floor 6, Raheja Titanium (Formerly known as M S K A & Associates) Westem Express Highway, Geetanjali Chartered Accountants MRa ui ml bw aa iy 4Co 0l 0o 0n 6y 3, R Ia NDm AN agar, Goregaon (E) Tel: +91 22 6974 0200 Independent Auditor’s Review Report on Standalone unaudited financial results of Marksans Pharma Limited for the quarter pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. To The Board of Directors of Marksans Pharma Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results of Marksans Pharma Limited (hereinafter referred to as ‘the Company’) for the quarter ended 30 June 2026 (‘the Statement’) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘the Regulations’). 2. This Statement, which is the responsibility of the Company’s Management and has been approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’, prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued thereunder (‘Ind AS 34’) and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For M'S K A & Associates LLP (Formerly known as M S K A & Associates) Chartered Accountants ICAI Firm Registration No.105047W/W101187 Nitin Tiwari Partner Membership No.:118894 UDIN: 2611 R394 RE THBI 3236 Place: Mumbai Date:12 August 2026 Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India Tel: +9122 6974 0200 | LLPIN: ACT-3789 Ahmedabad | Bengaluru | Chandigarh | Chennai | Coimbatore| Goa | Gurugram | Hyderabad | Kochi | Kolkata| Pune vwrw.mska,in MARKSANS PHARMA LIMITED TeleR pe hgi os nt ee Nr oe .d : O 0f 2f 2ic -e 4: 0 01 11 t 2h 0 0F 0l ,oo Wr e, bG sr ia tn ed :e ‘u wr, w wVC .eI mN e a: r r aL k D2 se4 as1 na s1 l p0 hM E axH t r1 e m9 n a9 s .2 i cP o oL n m C ,R0 o8 Ea -6 d m3 , a6 iO4 ls : h ci owa mr pa a, n yA snd eh ce rr e! t a[ rWe ys @t m] a, rM ku sm ab na sl p- h4 a0 r0 m0 a5 .3 c om STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026 QUARTEZ Nmi Dl Eli Do n except per equi Yt Ey As Rha Ere d Dat Ea) sr. 30 June 2026 | 31 March 2026 | 30 June 2025 | 31 Mar 2026 No. PARTICULARS (UNAUDITED) (R( efA oU rD I NT oE teD ) 3 ) {UNAUDITED) | (AUDITED) 1 [Revenue from operations. 2 |Other income, net (Refer note 5) 3,211.87 3,615.73 -+ 3,197.34 13,414.76 3 [Total Income (1+2) 174.70 274.75 20.10 1.035.33 Expenses 3,386.57 3,890.48 3,217.44 14,450.09 A |Cost of malerials consumed B |Purchase of stock-in-trade 1.416.43 1,594.82 1,452.77 6,024.27 ¢ [ aC nh da sn tg oe cs -i in ni -n tv re an dt eo ries of finished goods, work-in-progress 180.26 13259 227.98 730.62 D [Employee benefits expense (18.23) 25.84 (32.91) 32.95 E |Finance costs 317.75 32015 279.04 121977 GF || OD te hp er re c ei xa pt eio nn a en sd amortisation expense 873 .. 74 60 873 .. 55 63 813 .. 80 82 341 23 ,. 32 07 4 |Total Expenses 494.62 473.41 569.92 2,171.48 5 |Profit Before Tax (3-4) 2,481.99 2,646.90 2,581.70 10,534.66 |T ax Expense: 904.58 1,243.58 635.74 3,81543 (2) Current tax (b) Current tax for earlier period 213.90 301.08 14538 851.21 (c) Deferred tax (0.10) - - 11.70 6 |Total Tax Expense 0.41 2327 9.80 45.54 7 |Profit Aftor Tax (5-6) 214.21 324.35 155.18 908.45 Other Comprehensive Income 690.37 919.23 480.56 3,006.98 ltems that will not be reclassified to profit or loss. [ TR ae xm oe na s au br oe vm ee nts of the net defined benefit plans 3.48 344 {1.01)] 13.91 8 |Other Comprehensive Income (0.88)] (0.87) 025 (3.50) 9 |Total Comprehensive Income (7+8) 6922 ,. 96 70 9212 .5 87 47( 90 ..7 86 0)| 3,0110 7. .4 31 1 110 |O|P ta hi ed r u ep q uE iq tu yi ty Share Capital (face value 21 each fully paid) 453.16 453.16 453.16 453.16 12 |Eamings per equity share of 21 each* 16,069.94 DilBa us ti ec d| 1 1. 55 22 2 2, 00 33 1 1. .0 06 6 6. .6 64 *EPS s not annualised for the quarter ended 30 June 2025, 31 March 2026 and 30 Juma 2075 MARKSANS PHARMA LIMITED NOTES TO STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026 1 S uA tT tu nhh ad mee ti o ut dSs t E it oC B fa r Io in y m ed ( dm Aa L ul i i cdo st oi tn t nite ce no lge ru us n sa aa io nnu of dd nd ,t i Da ht iee p sd p cC r lf oo oi smvn ue pa rn d a ec ni b Ra yyl e h qtr uae h ivs e reu el Bt c mos a ea r no r r tf d i s e )t do h fe o R euDC gti uo r la [Showing first 8,000 characters — download PDF for full document]